By Anna Rose Welch, editor, Biosimilar Development
As the buck falls on physicians and healthcare systems to better control the cost of care, I wanted to hear from Dr. Chadi Nabhan about the value-based care models he’s been watching and how biosimilars (and biobetters) could fit into the overarching goals of these arrangements.
By Valerie Phillips, Michael Noble, and Mark Humphries, PA Consulting
To illustrate how delivery device development is evolving in practice, we will use the example of respiratory inhalers. This is a well-established treatment modality, with mature technology solutions available, but one where you can envisage a number of future changes enabled by technology.
By Martin Gonzalez, Ph.D.,Pfizer CentreOne Contract Manufacturing
The main culprit of a failing biologics drug is usually a flawed formulation. Selecting the right formulation is a complex task. In many cases, the challenge of optimizing a formulation’s ingredients becomes finding just the right balance. This article explores some of the chief components of biologics formulations.
The most widely used cell lines for biopharmaceutical production of therapeutic proteins originate from CHO cells. This application note compares cell growth and recombinant protein production of multiple Chinese hamster ovary (CHO) cell clones when cultured in HyClone ActiPro basal medium and Cell Boost 7a and 7b feeding supplements.